Dr. John Hovanesian with Harvard Eye Associates shares the exciting news that the FDA has approved Syfovre as the first-ever treatment for geographic atrophy secondary to age-related macular degeneration (AMD).

This breakthrough treatment demonstrated effectiveness in slowing the progression of geographic atrophy and preserving vision in those with AMD. This approval is significant for the millions of Americans living with AMD and offers hope for the future of treatment for this common eye disease.